Colleen Moretti, Assistant Editor for CURE®, joined MJH Life Sciences in November 2020. Colleen is a graduate of Monmouth University, where she studied communication with a focus in journalism and public relations. In her free time, she enjoys learning to cook new meals, spending time with her adopted beagle, Molly, or sitting on the beach with a good book. Email her at cmoretti@curetoday.com
Many Patients With Cancer Left Without A ‘Clear Path Forward’ After Withdrawing From Clinical Trials
August 26th 2021An expert from the University of Pennsylvania explains that better communication is needed between physicians and patients with cancer during clinical trials so that patients are better prepared for life after the clinical trial is over.
Read More
FDA’s Welireg Approval A ‘Complete Game Changer’ for Certain Cancers Associated With VHL Disease
August 24th 2021The approval of Welireg, according to an expert at Massachusetts General Hospital, is “extremely important” and will “dramatically” change how certain von Hippel-Lindau-associated cancers are treated.
Read More
Fear of Disease Progression Can Be ‘Debilitating’ For Some Parents of Childhood Cancer Survivors
August 17th 2021While it is normal for parents of childhood cancer survivors to experience anxiety and depression related to the fear of disease progression, parents are encouraged to seek help to ensure that the fear or progression doesn’t lead to debilitating consequences, according to an expert at Children’s Hospital of Philadelphia.
Read More
Educated Patients Are The ‘Key To The Success’ Of Their Cancer Therapy
August 11th 2021“More and more (patients and physicians) need to work together in partnership throughout the cancer journey in order to optimize and make the journey the best possible that we can for every single patient,” says an expert from the Roswell Park Comprehensive Cancer Center.
Read More
FDA Approval of Rylaze ‘Fulfills an Unmet Need’ for Group of Patients With Leukemia and Lymphoma
July 21st 2021The FDA approval of Rylaze provides certain patients with leukemia and lymphoma with an on-demand treatment option since the only other approved therapy is currently undergoing a shortage.
Read More